Trial Profile
Multiple centers, prospective, phase II trial of gemcitabine and docetaxel combination chemotherapy in patients with locally advanced/metastatic soft tissue sarcoma or imatinib mesylate refractory advanced/metastatic malignant gastrointestinal stromal tumor
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Gemcitabine (Primary)
- Indications Gastrointestinal stromal tumours; Soft tissue sarcoma
- Focus Pharmacogenomic; Therapeutic Use
- 07 Jul 2009 Planned end date changed from 1 Apr 2007 to 1 Dec 2009 as reported by ClinicalTrials.gov.
- 08 Nov 2006 New trial record.